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Abstract
Multidrug resistance-associated proteins (MRP) 2 and 4 are localized in proximal tubular epithelial cells and participate in the
renal elimination of xenobiotics. MRP2 has also been implicated in the renal and hepatic elimination of mercury. The current
study tested the hypothesis that MRP2 and MRP4 are involved in renal and hepatic handling of inorganic mercury (Hg2+).
We examined the disposition of Hg2+ in Mrp22/2 mice and assessed the transport of mercuric conjugates in inside-out
membrane vesicles containing human MRP4. Since MRP2 has been shown to utilize glutathione (GSH) for transport of select
substrates, we examined renal concentrations of GSH and cysteine and the expression of glutamate cysteine ligase (GCL) in
Mrp22/2 and FVB mice. The effect of Hg2+ exposure on renal GSH levels was also assessed in these mice. Our data suggest
that MRP2, but not MRP4, is involved in proximal tubular export of Hg2+. In addition, GSH levels are greater in Mrp22/2 mice
and exposure to Hg2+ reduced renal levels of GSH. Expression of GCL was also altered in Mrp22/2 mice under normal
conditions and following exposure to HgCl2. This study provides important novel data regarding the transport of Hg
2+ and
the effect of Hg2+ exposure on GSH levels.
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Introduction
The multidrug resistance-associated protein 2 (Mrp2) has been
implicated in the cellular export of various endobiotics and
xenobiotics, including chemotherapeutic agents and heavy metals
such as arsenic [1,2], platinum [2,3], cadmium [4,5], and mercury
[2,6–8]. In our previously published studies, we utilized TR2 rats
to implicate Mrp2 in the proximal tubular elimination of inorganic
mercury (Hg2+). TR2 rats are spontaneous mutants that lack
functional Mrp2 and since other proteins have been shown to be
altered significantly in these rats, we have chosen, in the current
study, to assess the role of Mrp2 in the corporal disposition and
handling of Hg2+ in a targeted Mrp2 knockout model, i.e., the
Mrp22/2 mouse. Therefore, the purpose of the current study was
to: 1) test the hypothesis that Mrp2 is involved in the transport of
mercuric species; 2) test the hypothesis that GSH status and
biosynthesis is altered by exposure to mercury. Although these
studies will be carried out in a manner similar to that used in our
previous studies, the current studies using Mrp22/2 mice are novel
and offer several advantages over the use of TR2 rats. First, the
use of a genetically engineered knockout mouse reduces the
possibility that the expression of other genes will be affected as a
consequence of the genetic modification. Secondly, the toxicology
and toxicokinetics of Hg2+ varies considerably between mice and
rats (Bridges, unpublished data) and the current studies will
provide important novel information regarding the handling of
inorganic mercury (Hg2+) in mice. Thirdly, the mouse is one of the
most popular research models used currently and thus, it is
important to fully characterize the handling of Hg2+ by these
animals. The data obtained from the current study may be utilized
for comparison to data obtained from future studies utilizing
mouse models. Although a portion of data obtained from the
current study tends to confirm our previous findings from TR2
rats, the use of Mrp22/2 mice to study the disposition and
handling of Hg2+ is novel and significant.
The results of our previous in vitro studies led us to suggest that
another transport mechanism, in addition to Mrp2, was involved
in the proximal tubular elimination of mercuric ions, particularly
when Hg2+ was conjugated to 2,3-bis(sulfanyl)propane-1-sulfonic
acid (formerly known as 2,3-dimercaptopropane-1-sulfonic acid;
DMPS). One possible candidate for this transport is Mrp4, which
is localized in the apical plasma membrane of proximal tubular
cells [9]. Owing to its localization and its ability to transport a
broad range of substrates, Mrp4 also appears to play an important
role in the renal elimination of endobiotics and xenobiotics. Prior
to the present study, no data have been published regarding the
ability of Mrp4 to transport Hg2+. In the current study, we utilized
inside-out membrane vesicles containing human MRP4 in order
to assess the ability of this carrier to mediate the transport of
DMPS-S-conjugates of Hg2+.
It is well-established that Hg2+ is a powerful oxidant that
accumulates rapidly in proximal tubular cells [10,11] and it has
been shown than exposure of rats to organic forms of mercury
(e.g., methylmercury) can induce the expression of glutamate
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cysteine ligase (GCL), the rate-limiting enzyme in the synthesis of
glutathione (GSH). This induction leads to an increase in the
synthesis of glutathione (GSH) [12–15]. In contrast, little is known
about the effects of inorganic mercury on the individual steps in
the biosynthetic pathway of GSH. Published studies indicate that
GSH levels increase following exposure to inorganic mercury [16],
but the mechanism behind this increase has yet to be character-
ized. In addition, tissue levels of GSH and the biosynthesis of GSH
has not been characterized in Mrp22/2 mice. Therefore, in the
current study, we assessed aspects of renal GSH biosynthesis and
the effects of mercury on this metabolic pathway in these mice. To
our knowledge, the present study not only represents the first
report of corporal disposition of Hg2+ in Mrp22/2 mice, but also it
represents the first assessment of GSH metabolism and the effects
of Hg2+ on GSH synthesis in the kidneys of these mice.
Methods
Ethics Statement
All experiments utilizing animals were approved by the Mercer
University Institutional Animal Care and Use Committee
(IACUC, Permit A1108009). Animals were handled in accordance
with the NIH Guide for the Care and Use of Laboratory Animals.
Animals
Breeder pairs of Mrp22/2 mice [17] were obtained from
Taconic (Germantown, NY) and were mated in our animal care
facility. Friend Virus B (FVB) mice, which were used as control
mice, were obtained from Charles River Laboratories (Wilming-
ton, MA) and mated in our facility. All animals were provided a
commercial laboratory diet (Tekland 6% rodent diet, Harlan
Laboratories) and water ad libitum throughout all aspects of
experimentation.
Manufacture of [203Hg]
The protocol for manufacturing radioactive mercury ([203Hg])
has been described previously [18,19]. Briefly, three milligrams of
mercuric oxide were sealed in quartz tubing and were irradiated
by neutron activation for 4 weeks at the Missouri University
Research Reactor (MURR) facility. After irradiation, the mercuric
oxide was dissolved in 1 N HCl. The radioactivity of the solution
was determined using an Ion Chamber survey meter (Fluke
Biomedical, Everett, WA). The specific activities of the [203Hg]
ranged from 6–12 mCi/mg.
Injection of Mice with [203Hg]
FVB and Mrp22/2 mice, weighing 25–30 g, were injected
intraperitoneally (i.p.) with a non-toxic dose (0.5 mmol ? kg21 ?
8 mL21) of HgCl2 (designed to deliver 1 mCi [203Hg] per mouse).
This dose is equivalent to 135.75 mg ? kg21 HgCl2. Mice were
dosed according to weight with a volume of 8 mL ? kg21. Each
mouse strain was divided randomly into two groups of four mice
each, following which mice were placed individually in metabolic
cages. Twenty-four and twenty-eight hours after injection with
HgCl2, one group of Mrp
2/2 mice and one group of FVB mice
were injected i.p. with 100 mg ? kg21 ? 8 mL21 DMPS. At the
same time, the remaining Mrp22/2 and FVB mice were injected
i.p. with 8 mL ? kg21 normal saline. Forty-eight hours after
injection with HgCl2, mice were injected with a mixture of
ketamine (70 mg ? kg21) and xylazine (30 mg ? kg21) and were
sacrificed via exsanguination 48 hours. Organs were harvested for
determination of mercury content.
Collection of Tissues, Organs, Urine and Feces
At the time of sacrifice, mice were anesthetized with an
intraperitoneal overdose of ketamine (70 mg ? kg21) and xylazine
(30 mg ? kg21). A 0.5-mL sample of blood was obtained from the
inferior vena cava. Approximately 0.1 mL was placed in a
polystyrene tube for estimation of [203Hg] content. The remaining
0.4 mL was placed in a blood separation tube in order to separate
plasma from the cellular components of blood. Total blood
volume was estimated as 6% of total body weight [20].
Each kidney was removed, weighed and cut in half along a
transverse plane. A 3-mm transverse slice of the left kidney was
utilized for separation of cortex (S1 and S2 proximal tubular
segments) and outer stripe of outer medulla (S3 proximal tubular
segments). Each zone of the kidney was weighed and placed in a
separate polystyrene tube for estimation of [203Hg] content. In
addition, a small slice of left kidney was frozen in liquid nitrogen
for future RNA isolation. One-half of the right kidney was frozen
in liquid nitrogen for future HPLC analyses. The liver was then
excised, weighed, and a 1-g section of liver was removed for
determination of [203Hg] content.
Urine and feces were collected for 24 h and 48 h after injection
with HgCl2. There were no significant differences in urine volume
or fecal mass among animals. Urine from each animal was mixed
and a 0.1-mL sample was weighed and placed in a polystyrene
tube for estimation of [203Hg] content. All of the feces excreted by
each animal during each 24-h period were counted to determine
the total fecal content of [203Hg] excreted by each animal. The
content of [203Hg] in each sample was determined using standard
isotopic methods and by counting in a Wallac Wizard 3 automatic
gamma counter (Perkin Elmer, Boston, MA).
High Performance Liquid Chromatography (HPLC)
Concentrations of GSH and Cys in renal tissues from Mrp22/2
and FVB mice injected intraperitoneally with 0.5 mmol ? kg21 ?
8 mL21 or 10 mmol ? kg21 ? 8 mL21 HgCl2 were measured using
HPLC. Tissues were frozen in liquid nitrogen, pulverized and then
homogenized in 10% (v/v) perchloric acid. Samples were
centrifuged for 10 min at 12,0006g and the acid-soluble fraction
was utilized for analyses. An aliquot of the acid-soluble fraction
was combined with bathophenanthroline disulfonic acid (BPDS)
and c-glutamyl glutamate in 70% perchloric acid. [21] From this
mixture, a 0.5-mL aliquot was removed and derivatized using
iodoacetate and 1-fluoro-2,4-dinitrobenzene. Separation of deriv-
atives was achieved with a Shimadzu SCL-10A solvent delivery
system fitted with a mBondapak amine-equivalent 10 mm column
(9.6 mm x 10 cm; ES Industries, West Berlin, NJ) using a
methanol-acetate mobile phase with gradient elution. Derivatives
were detected at 365 nm using a Shimadzu SPD-10A detector.
Quantification was based on known standards of GSH or Cys. To
control for inter-sample variation, peak areas were normalized to
the internal standard (c-glutamyl glutamate).
Vesicular Transport Assays
Inside-out membrane vesicles were prepared from human
embryonic kidney (HEK293) cells expressing human MRP2 or
MRP4 in the Bac-to-Bac vector as described previously [22].
Control vesicles were prepared from HEK293 cells mock-
transduced with the same vector, containing the enhanced yellow
fluorescent protein (EYFP) gene. MRP2 and MRP4 transport
activity was validated by measuring the uptake of [3-H]-
methotrexate as described previously [22,23]. Vesicular transport
assays were carried out using a rapid filtration method according
to a published protocol [22,23]. Briefly, DMPS-S-conjugates of
Hg2+ were formed by mixing 5 mM [203Hg] with 12.5 mM DMPS
GSH Status and Mercury Disposition in Mrp22/2 Mice
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in incubation buffer (250 mM sucrose, 10 mM Tris/HCl, pH 7.4)
supplemented with 10 mM MgCl2, 10 mM creatine phosphate
and 100 mg/ml creatine phosphokinase in the presence of 4 mM
ATP or AMP). Incubation buffer containing DMPS-S-conjugates
of Hg2+ was added to vesicle mixture (7.5 mg protein) and
incubated for 30 seconds at 37uC. Following incubation, ice-cold
buffer containing 1 mM DMPS (to remove bound Hg) was added
and each sample was filtered through a Multiscreen plate
(0.45 mm; Millipore, Billarica, MA). Filters were removed and
radioactivity contained on filter was determined using liquid
scintillation spectroscopy.
In order to assess ATP-dependent transport, the amount of
[203Hg] associated with vesicles in the presence of AMP was
subtracted from that in the presence of ATP.
RNA Isolation and Real-time PCR Analyses
Kidneys from Mrp22/2 and FVB mice injected intraperito-
neally with 0.5 mmol ? kg21 ? 8 mL21 or 10 mmol ? kg21 ? 8 mL21
HgCl2 were isolated at the time of animal sacrifice. A 3-mm
transverse slice was obtained from the central region of the kidney
and was frozen immediately in liquid nitrogen. At the time of
RNA isolation, frozen kidney slices were pulverized with a mortar
and pestle. TRIzol Reagent (Life Technologies, Grand Island, NY)
was added to the ground kidney and RNA was extracted
according to the manufacturer’s protocol.
Reverse transcription of 1 mg of RNA was carried out using
reverse transcriptase and random hexamers (Life Technologies).
Samples were subjected to the following conditions: 10 min at
25uC; 60 min at 42uC; 4 min at 95uC. For real-time PCR
analyses, 2 ml of the reverse transcriptase reaction were utilized
and samples were subjected to the following conditions: 2 min at
50uC; 10 min at 95uC; 1 min at 60uC for 40 cycles. Analysis of
glutamate cysteine ligase (GCL, formerly known as c-glutamyl
cysteine synthetase) was performed with an ABI Prism 7000
detection system using a Gene Expression Assay
(Mm0000514996_m1, Life Technologies) designed using a pub-
lished GCL sequence (NM_008129.3). Glyceraldehyde 3-phos-
phate dehydrogenase (Gapdh) was used as a reference gene. The
Gene Expression Assay for Gapdh (Mm99999915_g1) was
designed using a published sequence (NM_008084.2).
Data Analysis
Data from animal experiments are presented as percent of
administered dose of mercury or percent of administered dose of
mercury per gram of tissue (in order to account for potential
differences in body mass between animals). Data were then
analyzed with the Kolmogorov-Smirnov test for normality and
Levene’s test for homogeneity of variances. Following these tests,
data were analyzed using a one-way analysis of variance
(ANOVA), a 2-way ANOVA, or a 264 ANOVA to assess
differences among the means. When statistically significant F-
values were obtained with ANOVA, the data were analyzed using
Tukey’s post hoc multiple comparison test. A p-value of ,0.05 was
considered statistically significant. Each group of animals con-
tained three or four mice. All data are expressed as mean 6
standard error.
Results
Disposition of Mercuric Ions in Mouse Tissues
Approximately 30% of a 0.5 mmol ? kg21 dose of Hg2+ was
detected in the total renal mass of FVB mice 48 h after exposure to
HgCl2 and treated subsequently with saline (Figure 1). In contrast,
nearly 60% of the administered dose of Hg2+ was detected in the
total renal mass of corresponding Mrp22/2 mice. Treatment of
FVB mice with DMPS (100 mg ? kg21 ? 8 mL21) reduced the
renal burden of Hg2+ by over 50% (Figure 1). When Mrp22/2
mice were treated with the same dose of DMPS, the renal burden
of Hg2+ was found to be significantly lower than that in Mrp22/2
mice treated with saline.
The content of mercuric ions in the renal cortex of Mrp22/2
mice exposed to HgCl2 and treated subsequently with saline was
approximately twofold greater than that of corresponding FVB
mice (Figure 2A). Treatment with DMPS significantly reduced the
cortical content of Hg2+ in FVB but not in Mrp22/2 mice.
Similarly, the content of Hg2+ in the outer stripe of the outer
medulla of kidneys from Mrp22/2 mice was significantly greater
than that from corresponding FVB mice (Figure 2B). Treatment
with DMPS significantly reduced the content of Hg2+ in the outer
stripe of the outer medulla in both strains of mice.
The hepatic burden of Hg2+ in Mrp22/2 mice exposed to
HgCl2 and treated subsequently with saline was significantly
greater than that in corresponding FVB mice (Figure 3).
Treatment with DMPS significantly reduced the hepatic burden
of Hg2+ in FVB mice. In contrast, when Mrp22/2 mice were
treated with DMPS, the amount of Hg2+ detected in liver
increased significantly (Figure 3).
Approximately 1.3 percent of the administered dose of Hg2+
was detected in blood of both groups of Mrp22/2 mice (saline
and DMPS). The amount of Hg2+ detected in blood of FVB mice
treated with saline was also approximately 1.3 percent of the
administered dose. In contrast, the hematologic burden of Hg2+ in
FVB mice exposed to HgCl2 and treated subsequently with DMPS
was approximately 0.7 percent of the administered dose, which
was significantly different from that of all remaining groups of
mice. Approximately 75% of Hg2+ was associated with the cellular
components of blood while the remaining 25% was detected in
plasma. This pattern of distribution was similar in all groups of
mice.
The amount of Hg2+ in urine collected over a 48 h-period from
FVB mice exposed to HgCl2 followed by treatment with saline was
significantly greater than that from corresponding Mrp22/2 mice
(Figure 4). Treatment with DMPS significantly increased the
urinary excretion of Hg2+ in both, FVB and Mrp22/2 mice.
Similarly, fecal excretion of Hg2+ from FVB mice exposed to
HgCl2 and treated with saline was significantly greater than that
by corresponding Mrp22/2 mice (Figure 5). Treatment with
DMPS significantly increased fecal excretion of Hg2+ by both
strains of mice.
Transport of DMPS-S-conjugates of Hg2+ in Membrane
Vesicles
DMPS-S-conjugates of Hg2+ were formed by incubation of
5 mM HgCl2 with 12.5 mM DMPS at room temperature for five
minutes. Transport of DMPS-S-conjugates of Hg2+ was measured
in control vesicles and in vesicles containing MRP2 or MRP4
(Figure 6). ATP-dependent uptake of Hg2+ was significantly
greater in MRP2-containing vesicles than in control vesicles. In
contrast, the amount of Hg2+ associated with MRP4-containing
vesicles was not significantly different from that of control vesicles.
HPLC Analyses of GSH and Cysteine in Kidneys from FVB
and Mrp22/2 Mice
HPLC analyses of GSH in kidneys from FVB and Mrp22/2
mice (not exposed to HgCl2) indicate that the concentration of
GSH was significantly greater in kidneys from Mrp22/2 mice than
that in kidneys from corresponding FVB mice (Figure 7A).
GSH Status and Mercury Disposition in Mrp22/2 Mice
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Interestingly, exposure of mice to 0.5 mmol ? kg21 HgCl2 reduced
the concentration of GSH in both strains of mice by approx-
imately 50%. The renal concentration of GSH remained greater
in Mrp22/2 mice than in FVB mice. Interestingly, treatment of
FVB mice with 10 mmol ? kg21 HgCl2 did not significantly alter
the renal concentration of GSH. In contrast, when Mrp22/2 mice
were exposed to 10 mmol ? kg21? 8 mL21 HgCl2, the renal
concentration of GSH was reduced by only 25% (Figure 7A).
The renal concentration of Cys in unexposed Mrp22/2 mice
was not significantly different from that in corresponding FVB
mice (Figure 7B). When mice were treated with 0.5 mmol ? kg21
HgCl2, the renal concentration of Cys, in each strain, was reduced
by approximately 35% (Figure 7B). Interestingly, after treatment
with 10 mmol ? kg21 HgCl2, the renal concentration of Cys was
reduced by approximately 60% in Mrp22/2 mice and by
approximately 40% in FVB mice (Figure 7B).
Real-time PCR Analyses of Glutamate Cysteine Ligase
(GCL)
The renal expression of GCL (formally c-glutamylcysteine
synthetase) was significantly lower in Mrp22/2 mice not exposed
to HgCl2 than in corresponding FVB mice (Figure 8). Following
exposure of FVB mice to 0.5 mmol ? kg21 HgCl2, the expression of
GCL increased by approximately 50%. In Mrp22/2 mice,
exposure to 0.5 mmol ? kg21 HgCl2 resulted in a two-fold increase
in the expression of GCL. When FVB mice were exposed with
10 mmol ? kg21 HgCl2, the expression of GCL increased nearly
3.5-fold. Treatment ofMrp22/2 mice with 10 mmol ? kg21 HgCl2,
increased the expression of GCL by approximately 19-fold.
Discussion
The current dispositional studies in Mrp22/2 mice demonstrate
that within the kidneys, the content of Hg2+ in the renal cortex of
Mrp22/2 mice was twofold greater than that in corresponding
FVB mice. In the outer stripe of the outer medulla, the content of
Hg2+ was about 25% greater in Mrp22/2 mice than in FVB mice.
Interestingly, in kidneys of Mrp22/2 mice, the amount of Hg2+ in
the renal cortex was twofold greater than that in the outer stripe of
the outer medulla. This finding is likely due to preferential
accumulation of mercuric ions in S1 and S2 proximal tubular
segments [11], which are the primary sites of Mrp2 expression and
localization [24]. In addition, urinary excretion of mercuric ions
was lower in Mrp22/2 mice than in control mice, which supports
the idea that, in the absence of Mrp2, mercuric ions are retained
within proximal tubular epithelial cells and consequently, are not
excreted in urine. The present findings, combined with previous
data from TR2 rats [6,7,25], provide substantial, cross-species
evidence indicating that Mrp2 plays a significant role in the export
of mercuric ions from proximal tubular cells. In addition, these
data represent the first characterization of mercury handling in
Mrp22/2 mice and indicate that these mice are a viable model for
studies on the role of Mrp2 in the handling and disposition of
Hg2+.
A role for Mrp2 in the hepatobiliary excretion of mercuric ions
was initially proposed by Sugawara and colleagues [8]. They
showed that mercuric ions were retained in the liver of Mrp2-
deficient Eisai hyperbilirubinemic (EHB) rats. Similarly, our data
from TR2 rats also suggest that Mrp2 is involved in the
hepatobiliary export of mercuric ions [6,7,25]. In the current
study, the hepatic burden of mercury was significantly greater in
Mrp22/2 mice than in FVB mice. In addition, fecal excretion of
mercuric ions was lower in Mrp22/2 mice than in FVB mice.
Together, these data provide significant support for the hypothesis
that Mrp2 plays an important role in the elimination of mercuric
ions from hepatocytes.
When Mrp22/2 mice were treated with the chelator/complex-
ing agent, DMPS, subsequent to exposure to Hg2+ the renal
burden of Hg2+ in both, control and Mrp22/2 mice, was reduced
significantly. We have hypothesized previously that DMPS forms
complexes with mercuric ions intracellularly and that these
complexes are transported out of cells via Mrp2. Because
treatment of Mrp2-/2 mice with DMPS was able to reduce the
renal burden of mercury to some extent, we conclude that another
transport mechanism, in addition to Mrp2, is involved in the
DMPS-mediated export of mercuric ions from proximal tubules. A
Figure 1. Content of Mercury in the Total Renal Mass of Mrp22/2 and FVB Mice. Mrp22/2 and FVB mice were injected intraperitoneally with
a dose of 0.5 mmol ? kg21 ? 8 mL21 HgCl2. Kidneys were harvested 48 h after injection with HgCl2. Data represent mean 6 SE of kidneys from four
mice. *, significantly different from mean of corresponding FVB mice (p,0.05). +, significantly different from mean of mice from same strain treated
with saline (p,0.05).
doi:10.1371/journal.pone.0073559.g001
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putative candidate for this process is Mrp4. Owing to similarities
in substrate specificity of Mrp2 and Mrp4 [26] and the fact that
Mrp4 is localized in the apical membrane of proximal tubular
epithelial cells [9], we postulated that Mrp4 may also play a role in
the proximal tubular export of mercuric ions. Surprisingly, the
results of our membrane vesicle experiments suggest that DMPS-
S-conjugates of Hg2+ are not substrates of MRP4. In contrast,
DMPS-S-conjugates of Hg2+ were found to be transported readily
in inside-out membrane vesicles containing MRP2. Although
whole-animal dispositional findings from our laboratory indicate
that an additional transporter, other than MRP2, plays a role in
the export of mercuric ions from proximal tubular cells, the
current in vitro findings suggest that this carrier is likely not MRP4.
Other possible candidates that may participate in the export of
DMPS-S-conjugates of Hg2+ include the organic anion transporter
5 (OAT5; SLC22A10) and/or the multidrug resistance protein 1
(MDR1/P-glycoprotein; ABCB1), both of which are localized in
the luminal membrane of proximal tubular cells [27–29].
Interestingly, when Mrp22/2 mice were treated with DMPS,
the hepatic burden of Hg increased significantly. We believe that
this increase may be due to binding of DMPS to mercuric ions in
other tissues and subsequent mobilization of the mercuric ions.
Given the role of the liver in drug processing and other metabolic
processes, it is reasonable to suggest that mobilized DMPS-Hg
complexes are delivered to the liver in an attempt to process and
eliminate this toxicant.
MRP2 has been shown to transport GSH and GSH-S-
conjguates, as well as utilize it as a co-factor for the transport of
certain other substrates. In addition, GSH is involved in numerous
cellular processes including drug metabolism, maintenance of
cellular redox status, and cellular stress responses, such as that
which occurs following exposure to Hg2+ [16,30]. Because GSH
plays an important role in cellular responses following exposure to
Hg2+, we assessed the renal levels of GSH in Mrp22/2 and FVB
mice treated with saline or HgCl2 in order to 1) determine if
differences in GSH synthesis exist between these two strains of
mice (that can be attributed to the absence of Mrp2) and 2) to
examine the effects of HgCl2 exposure on GSH status. It is logical
to postulate that in the absence of Mrp2, substrates of this
transporter, including GSH, may accumulate within cells.
Figure 2. Content of Mercury in the Renal Zones of Mrp22/2 and FVB Mice. Mrp22/2 and FVB mice were injected intraperitoneally with a
dose of 0.5 mmol ? kg21 ? 8 mL21 HgCl2. Samples from cortex (A) or outer stripe of outer medulla (B) were harvested 48 h after injection with HgCl2.
Data are presented as percent administered dose per milligram of tissue in order to account for differences in sample weight. Data represent mean6
SE of four mice. *, significantly different from mean of corresponding FVB mice (p,0.05). +, significantly different from mean of mice from same strain
treated with saline (p,0.05).
doi:10.1371/journal.pone.0073559.g002
GSH Status and Mercury Disposition in Mrp22/2 Mice
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e73559
Therefore, it was not surprising that renal levels of GSH were
greater in Mrp22/2 mice than in FVB mice. In order to determine
if the increased levels of GSH were due to increased synthesis or
the lack of GSH export, we examined mRNA levels of glutamate
cysteine ligase (GCL), which is the rate-limiting enzyme required
for the synthesis of GSH. Interestingly, renal expression of GCL
was significantly lower in Mrp22/2 mice than in FVB mice,
suggesting that the increased levels of GSH in Mrp22/2 mice may
be due to the lack of GSH export rather than an increase in GSH
synthesis. The reduced expression of GCL in Mrp22/2 mice is
most likely the result of GSH-mediated feedback inhibition
wherein increased levels of GSH inhibit the expression of GCL
[31].
Given the oxidative nature of Hg2+ we chose to examine the
effects of exposure to this metal on renal GSH levels and
biosynthesis in Mrp22/2 and FVB mice To our knowledge, this
study represents the first examination of the effects of Hg2+
exposure on renal GSH levels and biosynthesis in these mouse
models. Exposure of animals to a non-toxic dose (0.5 mmol ? kg21)
of HgCl2 led to a reduction of renal GSH levels, possibly due to
Hg2+-induced depletion of intracellular GSH stores or inhibition
of GSH biosynthesis. Under these conditions, the renal concen-
Figure 3. Content of Mercury in Liver of Mrp22/2 and FVB Mice. Mrp22/2 and FVB mice were injected intraperitoneally with a dose of
0.5 mmol ? kg21 ? 8 mL21 HgCl2. Samples of liver were harvested 48 h after injection with HgCl2. Data represent mean6 SE of liver samples from four
mice. *, significantly different from mean of corresponding FVB mice (p,0.05). +, significantly different from mean of mice from same strain treated
with saline (p,0.05).
doi:10.1371/journal.pone.0073559.g003
Figure 4. Content of Mercury in Urine of Mrp22/2 and FVB Mice. Mrp22/2 and FVB mice were injected intraperitoneally with a dose of
0.5 mmol ? kg21 ? 8 mL21 HgCl2. Urine was collected 24 h and 48 h after injection with HgCl2. Data represent mean 6 SE of urine collected from four
mice. *, significantly different from mean of corresponding FVB mice (p,0.05). +, significantly different from mean of mice from same strain treated
with saline (p,0.05).
doi:10.1371/journal.pone.0073559.g004
GSH Status and Mercury Disposition in Mrp22/2 Mice
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tration of Cys, which is the rate-limiting substrate of GSH
synthesis, was also reduced, perhaps due to its utilization for GSH
biosynthesis. Indeed, renal expression of GCL was increased
twofold in both, FVB and Mrp22/2 mice following exposure to
HgCl2, suggesting an attempt to increase the synthesis of GSH in
proximal tubular cells.
Previous studies in rats have shown that increasing in the dose of
Hg2+ leads to enhanced renal cellular concentrations of GSH [16].
Therefore, in the current study, FVB and Mrp22/2 mice were also
exposed to a greater, albeit non-toxic dose of HgCl2 (10 mmol ?
kg21). In these mice, the overall renal levels of GSH were greater
than those in mice exposed to a non-toxic (0.5 mmol ? kg21) dose
of HgCl2. When we compared the renal levels of GSH in FVB and
Mrp22/2 mice exposed to saline with those in mice exposed to
10 mmol ? kg21 HgCl2, we found that exposure to a larger dose of
HgCl2 did not alter the overall renal levels of GSH in FVB mice,
but did reduce the renal concentration of GSH in Mrp22/2 mice.
This finding may be related to the observation that the baseline
expression of GCL was lower in Mrp22/2 mice than in FVB mice
(due to feedback inhibition). Therefore, FVB mice may be able to
synthesize GSH at a faster rate than Mrp22/2 mice. Also,
following exposure to 10 mmol ? kg21 HgCl2, renal levels of Cys
were reduced significantly in both strains of mice, possibly due to
enhanced utilization for GSH synthesis.
Figure 5. Content of Mercury in Feces of Mrp22/2 and FVB Mice. Mrp22/2 and FVB mice were injected intraperitoneally with a dose of
0.5 mmol ? kg21 ? 8 mL21. Feces were collected 24 h and 48 h after injection with HgCl2. Data represent mean6 SE of feces collected from four mice.
*, significantly different from mean of corresponding FVB mice (p,0.05). +, significantly different from mean of mice from same strain treated with
saline (p,0.05).
doi:10.1371/journal.pone.0073559.g005
Figure 6. Transport of DMPS-S-conjugates of Hg2+ into Inside-out Membrane Vesicles. Inside-out membrane vesicles expressing human
MRP2, MRP4, or EYFP (control) were exposed to DMPS-S-conjugates of HgCl2 for 30 s at 37uC. Data represent mean 6 SE of four replicates. +,
significantly different from mean of control vesicles (p,0.05).
doi:10.1371/journal.pone.0073559.g006
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The expression of GCL in each strain of mouse corresponded
with measured levels of GSH and Cys. As expected, expression of
GCL increased significantly in both strains of mice after exposure
to a 10 mmol ? kg21 dose of HgCl2, suggesting that synthesis of
GSH was initiated. The expression of GCL was significantly
greater in mice exposed to a dose of 10 mmol ? kg21 HgCl2 than
that observed following exposure to 0.5 mmol ? kg21 HgCl2,
suggesting that the need to synthesize GSH was greater in animals
treated with a higher dose of HgCl2.
In summary, the present data from a targeted knockout mouse
model (e.g., Mrp22/2) provide substantive novel evidence
supporting a role of Mrp2 in the renal and hepatic elimination
of mercuric ions. In addition, we provide new data from inside-out
membrane vesicles containing human MRP2 or MRP4 suggesting
that MRP2, but not MRP4, plays a significant role in DMPS-
mediated elimination of mercuric ions from proximal tubules. The
present study is also the first to show differences in renal GSH
biosynthesis and GCL expression between Mrp22/2 and FVB
mice and the ability of HgCl2 to alter these parameters. Overall,
this study presents novel findings that provide valuable informa-
tion regarding the transport of mercuric species and the effects of
these mercuric species on select cellular processes in kidneys.
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Figure 7. HPLC Analysis of Renal Glutathione and Cysteine Concentration in Mrp22/2 and FVB Mice. HPLC analyses of renal GSH (A) or
cysteine (Cys) (B) were carried out on 3-mm slices of kidneys from Mrp22/2 and FVB mice exposed to saline, 0.5 mmol ? kg21 ? 8 mL21, or 10 mmol ?
kg21 ? 8 mL21 HgCl2. Renal levels of GSH or Cys were normalized to known GSH or Cys standards, respectively. Data represent mean 6 SE of nine
samples from three different animals. *, significantly different from the mean of corresponding FVB mice (p,0.05). +, significantly different from the
mean of the same strain of mouse treated with saline (p,0.05). #, significantly different from the mean of the corresponding group of mice treated
with 0.5 mmol kg21 HgCl2.
doi:10.1371/journal.pone.0073559.g007
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